Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

30 August 2019 : Clinical Research  

Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab

Ning Shao12BCDE, Fangning Wan12BE, Yao Zhu12ADF, Dingwei Ye12AF*

DOI: 10.12659/MSM.916984

Med Sci Monit 2019; 25:6518-6522

Abstract

BACKGROUND: Nivolumab is approved for the treatment of advanced renal cell carcinoma (RCC). However, traditional overall survival (OS) or progression-free survival (PFS) do not reflect patient prognosis after initial management. Therefore, this study aimed to evaluate conditional overall survival (COS) and conditional progression-free survival (CPFS) in patients with advanced RCC treated with nivolumab.

MATERIAL AND METHODS: There were 847 patients with advanced RCC treated with first-line nivolumab plus ipilimumab (n=425) and sunitinib (n=422), and 821 patients were treated with second-line nivolumab (n=410) and everolimus (n=411). Primary endpoints were COS and CPFS. Individual patient data of PFS and OS were digitally reconstructed from two large randomized controlled trials (CheckMate 025 and CheckMate 214).

RESULTS: In first-line treatment, compared with sunitinib, improvement of one-year CPFS for the nivolumab plus ipilimumab group after living for 0.5 and 0.75 years were 14% (from 53.0% to 67.0%) and 16% (from 57.0% to 73.0%) higher than the one-year PFS of 6.5% (from 42.9% to 49.4%), with similar results for one-year COS following first-line treatment. For second-line treatment, compared with everolimus, the improvement of one-year CPFS for the nivolumab group after living for 0.5 and 0.75 years were 19% (from 25.0% to 44.0%) and 19% (from 27.0% to 46.0%) and significantly higher than the one-year PFS of 4.5% (from 18.5% to 23.0%).

CONCLUSIONS: Survival benefit for patients with advanced RCC from nivolumab (plus ipilimumab) compared with sunitinib was more evident from conditional survival (CS) analysis of first-line treatment.

Keywords: Carcinoma, Renal Cell, Immunotherapy, Survival, Kidney Neoplasms, Nivolumab, Progression-Free Survival

Add Comment 0 Comments

Editorial

01 November 2024 : Editorial  

Editorial: Artificial Intelligence (AI), Digital Image Analysis, and the Future of Cancer Diagnosis and Prognosis

Dinah V. Parums

DOI: 10.12659/MSM.947038

Med Sci Monit 2024; 30:e947038

0:00

In Press

Clinical Research  

Comprehensive Analysis of Immune Infiltration and Key Genes in Peri-Implantitis Using Bioinformatics and Mo...

Med Sci Monit In Press; DOI: 10.12659/MSM.941870  

Clinical Research  

High-Resolution Anorectal Manometry and Balloon Expulsion Test Outcomes in Functional Constipation: A Compa...

Med Sci Monit In Press; DOI: 10.12659/MSM.944599  

Clinical Research  

Plaque Removal and Gingival Bleeding Using Biodegradable Toothbrushes: Salvadora persica, Bamboo, and Nylo...

Med Sci Monit In Press; DOI: 10.12659/MSM.944469  

Clinical Research  

Comparative Analysis of Extended Curettage with Plate Fixation and Extended Curettage with Intramedullary N...

Med Sci Monit In Press; DOI: 10.12659/MSM.945157  

Most Viewed Current Articles

17 Jan 2024 : Review article   6,190,650

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research   1,908,656

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   695,192

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

07 Jan 2022 : Meta-Analysis   260,387

Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Dise...

DOI :10.12659/MSM.935074

Med Sci Monit 2022; 28:e935074

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750